In a letter from Dr Rizza to Dr Alison Smithies, the DHSS stated that BPL would start releasing 8Y prepared from tested donors from the middle of August, and by the end of September, if not sooner, all NHS Factor 8 would be from tested donors. Read more about In a letter from Dr Rizza to Dr Alison Smithies, the DHSS stated that BPL would start releasing 8Y prepared from tested donors from the middle of August, and by the end of September, if not sooner, all NHS Factor 8 would be from tested donors.
From May 1985, all Factor 8 issues by BPL/PFL had been heat treated under at least HT2 conditions. Read more about From May 1985, all Factor 8 issues by BPL/PFL had been heat treated under at least HT2 conditions.
All issues of Factor 8 were subjected to HT3 heat treatment. The product which was coded 8Y was made at both Oxford and Elstree. Read more about All issues of Factor 8 were subjected to HT3 heat treatment. The product which was coded 8Y was made at both Oxford and Elstree.
In the draft witness statement of Dr Snape, he stated that between May and October 1984 activities leading to the establishment of the 8Y process "began in earnest". Read more about In the draft witness statement of Dr Snape, he stated that between May and October 1984 activities leading to the establishment of the 8Y process "began in earnest".
Chiron Corporation identified, cloned and expressed proteins from Hepatitis non-A non-B virus, which may allow screening for previously undetectable disease. Read more about Chiron Corporation identified, cloned and expressed proteins from Hepatitis non-A non-B virus, which may allow screening for previously undetectable disease.
UK haemophilia reference centre directors sent a circular letter to all haemophilia centres with recommendations on choice on therapeutic products for the treatment of non-inhibitor patients with Haemophilia A, Haemophilia B or von Willebrand's Disease. Read more about UK haemophilia reference centre directors sent a circular letter to all haemophilia centres with recommendations on choice on therapeutic products for the treatment of non-inhibitor patients with Haemophilia A, Haemophilia B or von Willebrand's Disease.
Bruce L Evatt from the Center for Infectious Diseases wrote to Fred Feldman, Armour Pharmaceuticals regarding heat inactivation of LAV in clotting concentrates and two preliminary experiments that had been undertaken with regards to this. Read more about Bruce L Evatt from the Center for Infectious Diseases wrote to Fred Feldman, Armour Pharmaceuticals regarding heat inactivation of LAV in clotting concentrates and two preliminary experiments that had been undertaken with regards to this.
Dr Shanbrom stated that he tried to persuade the four major manufacturers of factor concentrates to use a detergent process for viral inaction in the mid to late 1970s. Read more about Dr Shanbrom stated that he tried to persuade the four major manufacturers of factor concentrates to use a detergent process for viral inaction in the mid to late 1970s.
David Castaldi from Hyland sent a memo to his distribution team about the decision to proceed with heat treating its product, on the basis not that it would eliminate hepatitis, but reduce the risk of it. Read more about David Castaldi from Hyland sent a memo to his distribution team about the decision to proceed with heat treating its product, on the basis not that it would eliminate hepatitis, but reduce the risk of it.
Dr Milton Mozen, director of biochemical research and development at Cutter, said that "Concern about hepatitis transmission" was the reason for experiments with heat treatment in the early 1970s. Read more about Dr Milton Mozen, director of biochemical research and development at Cutter, said that "Concern about hepatitis transmission" was the reason for experiments with heat treatment in the early 1970s.